• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SATB2 在骨未分化多形性肉瘤中的表达。

SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone.

机构信息

Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Am J Clin Pathol. 2022 Aug 4;158(2):235-241. doi: 10.1093/ajcp/aqac033.

DOI:10.1093/ajcp/aqac033
PMID:35311957
Abstract

OBJECTIVES

SATB2 is a transcriptional regulator that plays an important role in osteoblastic differentiation. We examined the prevalence and potential significance of SATB2 expression in undifferentiated pleomorphic sarcoma (UPS) of bone.

METHODS

We examined 38 cases of bone UPS without osteoid. The male-to-female ratio was 1:1.4, with a median age of 48 years (range, 23-83 years). Tumors occurred primarily in the femur (n = 8) and ilium (n = 8), with a median tumor size of 9.5 cm (range, 1.8-27.0 cm). The median follow-up was 24.7 months (range, 2-82 months): 11 patients developed local recurrences, and 18 patients had metastases, mainly to lung and bone.

RESULTS

SATB2 expression (nuclear labeling ≥5%) was seen in 21 of 38 (55%) cases: 5 with focal (nuclear labeling 5%), 11 with patchy (nuclear labeling 5%-50%), and 5 with diffuse (nuclear labeling ≥50%) staining. Among this group, diffuse SATB2 expression demonstrated superior metastasis-free survival (P = .036) and event-free survival (P = .024). For comparison, 100 soft tissue UPS were stained; the majority were negative (75/100 [75%]).

CONCLUSIONS

UPS of bone demonstrated more frequent SATB2 expression compared with its soft tissue counterpart. In this series, diffuse SATB2 expression in UPS of bone was associated with better outcomes. Additional studies are still needed to determine its significance.

摘要

目的

SATB2 是一种转录调节因子,在成骨细胞分化中发挥重要作用。我们研究了 SATB2 在骨未分化多形性肉瘤(UPS)中的表达频率及其潜在意义。

方法

我们检查了 38 例无骨样组织的骨 UPS 病例。男女比例为 1:1.4,中位年龄为 48 岁(范围 23-83 岁)。肿瘤主要发生于股骨(n=8)和髋骨(n=8),肿瘤大小中位数为 9.5cm(范围 1.8-27.0cm)。中位随访时间为 24.7 个月(范围 2-82 个月):11 例患者出现局部复发,18 例患者发生转移,主要转移部位为肺和骨。

结果

38 例中 21 例(55%)SATB2 表达(核标记≥5%):5 例为局灶性(核标记 5%),11 例为斑片状(核标记 5%-50%),5 例为弥漫性(核标记≥50%)染色。在这一组中,弥漫性 SATB2 表达显示出更好的无转移生存(P=0.036)和无事件生存(P=0.024)。为了比较,我们对 100 例软组织 UPS 进行了染色;大多数为阴性(75/100 [75%])。

结论

与软组织 UPS 相比,骨 UPS 中 SATB2 的表达更为频繁。在本系列中,骨 UPS 中弥漫性 SATB2 表达与更好的结果相关。仍需要进一步的研究来确定其意义。

相似文献

1
SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone.SATB2 在骨未分化多形性肉瘤中的表达。
Am J Clin Pathol. 2022 Aug 4;158(2):235-241. doi: 10.1093/ajcp/aqac033.
2
Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.与其他高级别原发性骨肉瘤相比,富含AT序列结合蛋白2(SATB2)的表达对骨肉瘤敏感,但可能不具有特异性。
Histopathology. 2016 Jul;69(1):84-90. doi: 10.1111/his.12911. Epub 2016 Jan 26.
3
SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.SATB2 是骨和软组织肿瘤成骨细胞分化的一个新标志物。
Histopathology. 2013 Jul;63(1):36-49. doi: 10.1111/his.12138. Epub 2013 May 23.
4
[Significance of SATB2 in the pathologic diagnosis of osteosarcoma].SATB2在骨肉瘤病理诊断中的意义
Zhonghua Bing Li Xue Za Zhi. 2016 Sep 8;45(9):631-5. doi: 10.3760/cma.j.issn.0529-5807.2016.09.009.
5
Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.SATB2在原发性皮肤肉瘤样肿瘤中的表达:一个潜在的诊断陷阱。
Pathology. 2023 Apr;55(3):350-354. doi: 10.1016/j.pathol.2022.10.011. Epub 2023 Jan 10.
6
The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.SATB2免疫组化表达在鉴别骨肉瘤与其恶性骨肿瘤模仿者(如尤因肉瘤和软骨肉瘤)中的作用。
Pathol Res Pract. 2016 Sep;212(9):811-6. doi: 10.1016/j.prp.2016.06.012. Epub 2016 Jun 26.
7
SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.SATB2表达对妇科癌肉瘤的骨肉瘤成分敏感但不具有特异性:一项60例病例的临床病理研究
Int J Gynecol Pathol. 2017 Mar;36(2):140-145. doi: 10.1097/PGP.0000000000000301.
8
Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.地诺单抗治疗前后骨巨细胞瘤的组织形态计量学分析
Int J Surg Pathol. 2020 Dec;28(8):859-867. doi: 10.1177/1066896920920716. Epub 2020 May 19.
9
Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases.骨硬化性上皮样纤维肉瘤:9 例形态学、免疫表型和分子学研究结果。
Virchows Arch. 2021 Apr;478(4):767-777. doi: 10.1007/s00428-020-02953-y. Epub 2020 Oct 21.
10
Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.骨原发性上皮样梭形细胞纤维肉瘤:系列分析。
Am J Surg Pathol. 2014 Nov;38(11):1538-44. doi: 10.1097/PAS.0000000000000265.

引用本文的文献

1
The importance of marginal sclerosis in the recovery of mechanical strength after curettage of bone lesions.边缘性硬化在骨病变刮除术后力学强度恢复中的重要性。
Am J Transl Res. 2025 Jul 25;17(7):5641-5653. doi: 10.62347/GZLN4148. eCollection 2025.
2
Advances in research on SATB2 and its role in tumor development.SATB2的研究进展及其在肿瘤发生中的作用
Cell Biosci. 2025 Jul 28;15(1):111. doi: 10.1186/s13578-025-01439-1.
3
SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma: A Series with Comprehensive Biomarker and Molecular Studies.
SATB2是间变性甲状腺癌的一种新兴生物标志物:一项综合生物标志物和分子研究系列。
Endocr Pathol. 2024 Dec;35(4):432-441. doi: 10.1007/s12022-024-09833-0. Epub 2024 Nov 5.
4
Single-cell sequencing reveals the landscape of the tumor microenvironment in a skeletal undifferentiated pleomorphic sarcoma patient.单细胞测序揭示了一名骨骼未分化多形性肉瘤患者的肿瘤微环境图谱。
Front Immunol. 2022 Nov 16;13:1019870. doi: 10.3389/fimmu.2022.1019870. eCollection 2022.